Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

LVTX vs AQST: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AQST Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 3–5 Matrix Metrics)

AQST Overall Winner 6-Pillar Tally: LVTX 0 – 5 AQST (1 Tie) Matrix Metrics: LVTX 5 – 3 AQST

As of Nov 20, 2026, Aquestive Therapeutics, Inc. (AQST) is the stronger overall head-to-head candidate over LAVA Therapeutics N.V. (LVTX) in the Tradestie Institutional Equity Comparison Engine, winning 3–5 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LVTX carries a Unified Composite Score of 67.0/100 (BUY) at $1.74 (N/M Forward P/E, -431.9% operating margin), whereas AQST carries 62.9/100 (BUY) at $3.46 (N/M Forward P/E, -114.1% operating margin).

  • Composite vs. Pillar Nuance: While LVTX currently prints a higher short-term Unified Composite Score (67.0/100 BUY vs. AQST 62.9/100 BUY), AQST captures the overall institutional head-to-head verdict (3–5 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-114.1% vs. -431.9% operating margin) and revenue trajectory (-41.0% vs. +1313.6% YoY).
  • Technical & Structure Timing Caution: LVTX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3); meanwhile AQST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LVTX vs AQST
LVTX NASDAQ
LAVA Therapeutics N.V. Ordinary Shares
Pharmaceutical Preparations
$1.74
-3.87% 1D
Market Cap $45.8M
TTM Revenue $5.0M
Forward P/E N/M
Beta / 30D Vol -0.02β · 49% Vol
Unified Composite Score
67.0 / 100 BUY
Tech 75.0 Fund 63.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.7% over 20 days), RSI 62
RSI-14: 62.3 · SMA20: $1.65 · SMA50: $1.59
AQST NASDAQ Head-to-Head Winner
Aquestive Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$3.46
-6.61% 1D
Market Cap $465.7M
TTM Revenue $49M
Forward P/E N/M
Beta / 30D Vol 0.89β · 56% Vol
Unified Composite Score
62.9 / 100 BUY
Tech 54.0 Fund 68.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.9%), weak momentum, RSI 36
RSI-14: 36.5 · SMA20: $3.77 · SMA50: $4.23

6-Pillar Scorecard Institutional Category Breakdown (LVTX 0 – 5 AQST)

Columns: Metric · LVTX · AQST
1. Valuation Multiples AQST
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 9.2x 8.9x
2. Growth & Scale AQST
Revenue Growth (YoY) +1313.6% -41.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $5.0M $49M
Market Cap $45.8M $465.7M
3. Profitability & Quality AQST
Gross Margin 100.0% 65.3%
Operating Margin -431.9% -114.1%
Net Profit Margin 0.0% -162.3%
Return on Equity (ROE) -101.5% 0.0%
4. Balance Sheet & Cash Flow AQST
Cash Generation (TTM) -$21M EBITDA -$41M
Cash Flow Margin N/A -83.3%
Net Cash / Leverage $0.48 Book/Sh · -101.5% ROE $32M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AQST
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 87.9% (64th %ile)
Put/Call OI Skew N/A 0.98x (Balanced)
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Pharmaceutical Preparations Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LVTX (5) vs AQST (3)
Institutional Metric LVTX AQST Criterion Row Edge
Market Capitalization
Scale
$45.8M $465.7M Larger Scale AQST
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+1313.6% -41.0% Higher Growth LVTX
Operating Margin (TTM)
Profitability
-431.9% -114.1% Higher Margin AQST
Net Profit Margin
Profitability
0.0% -162.3% Higher Margin LVTX
Return on Equity (ROE)
Capital Efficiency
-101.5% 0.0% Higher ROE AQST
52-Week Range Position
Momentum
77% ($1–$2) 14% ($3–$7) Stronger Trend LVTX
Beta / 30D Volatility
Risk Regime
-0.02β · 49% Vol 0.89β · 56% Vol Lower Realized Risk LVTX
Unified Institutional Score
Composite Signal
67.0 / 100 (BUY) 62.9 / 100 (BUY) Higher Composite LVTX
Trailing 12M Revenue (USD)
Operating Scale
$5.0M $49M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% 65.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 9.2x EV/Rev N/M PEG · 8.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$21M EBITDA ($0.48 Book/Sh · -101.5% ROE) -$41M ($32M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AQST +0.27 pp
LVTX: -3.87% · AQST: -3.6%
3M Horizon AQST +0.27 pp
LVTX: -3.87% · AQST: -3.6%
6M Horizon AQST +0.27 pp
LVTX: -3.87% · AQST: -3.6%
1Y Horizon AQST +0.27 pp
LVTX: -3.87% · AQST: -3.6%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LVTX vs AQST. Trailing 12-month operating profitability (LVTX -431.9% vs AQST -114.1%) and valuation multiples (LVTX N/M vs AQST N/M Forward P/E) are benchmarked directly in Pillar 4 below.

LVTX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$5.0M
Gross Margin100.0%
Op. Margin-431.9%
ROE / Fwd P/E-101.5% · N/M
AQST ADR TTM Benchmark FX-Normalized USD
TTM Revenue$49M
Gross Margin65.3%
Op. Margin-114.1%
ROE / Fwd P/E0.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LVTX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LVTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AQST BREAKDOWN
61d in phase · OBV NEUTRAL
Current IV 87.9%
IV Percentile 64th %ile
Put/Call OI Skew 0.98x (Balanced)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact AQST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LVTX Moat Profile Cyclical / Execution-Driven Positioning
Pharmaceutical Preparations Operator
Competes within the Pharmaceutical Preparations value chain with $45.8M market capitalization and -431.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AQST Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $465.7M market capitalization and -114.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LVTX vs AQST Key Questions & Quantitative Answers

As of Nov 20, 2026, Aquestive Therapeutics, Inc. (AQST) is the stronger overall head-to-head candidate over LAVA Therapeutics N.V. (LVTX) in the Tradestie Institutional Equity Comparison Engine, winning 3–5 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LVTX carries a Unified Composite Score of 67.0/100 (BUY) at $1.74 (N/M Forward P/E, -431.9% operating margin), whereas AQST carries 62.9/100 (BUY) at $3.46 (N/M Forward P/E, -114.1% operating margin). Composite vs. Pillar Nuance: While LVTX currently prints a higher short-term Unified Composite Score (67.0/100 BUY vs. AQST 62.9/100 BUY), AQST captures the overall institutional head-to-head verdict (3–5 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-114.1% vs. -431.9% operating margin) and revenue trajectory (-41.0% vs. +1313.6% YoY). Technical & Structure Timing Caution: LVTX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3); meanwhile AQST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AQST leads the Growth & Scale pillar: LVTX posts +1313.6% YoY revenue growth and +0.0% YoY earnings growth on $5.0M TTM revenue (100.0% gross margin, -431.9% operating margin), compared with AQST at -41.0% YoY revenue growth and +0.0% YoY earnings growth on $49M TTM revenue (65.3% gross margin, -114.1% operating margin). On trailing 12-month operating scale, LVTX generates $5.0M in USD-normalized revenue versus $49M for AQST. In operating R&D and SG&A reinvestment, LVTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AQST.

AQST screens cheaper on headline valuation multiples. LVTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.2x EV/Revenue (unreported EBITDA margin), whereas AQST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 8.9x EV/Revenue (-83.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LVTX (-101.5% ROE) versus AQST (0.0% ROE) capital efficiency.

In options market volatility and institutional positioning, LVTX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 49% Vol realized risk). By comparison, AQST carries 87.9% implied volatility (64th %ile, Elevated (60th–80th %ile)), a 0.98x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.89β · 56% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.